That is manifest
in legal technology interest and investment, the rise of
managed legal service providers — both
in - house and outsourced — and a kick - start to innovation
in a profession /
industry characterized by stasis, limited consumer options, conservatism, resistance to
change, insularity, homogeneity, and elitism.
These factors include supplier's performance over the current contract term, the strength of the relationship with the supplier, the alignment of the current outsourcing model with customer's strategies and objectives, any
change in customer's operating model, strategy or requirement since the initial contract was executed, whether the customer expects that its operating model, strategy or requirement may
change during the renewal term, the capability of supplier to support customer future growth, supplier's innovation and flexibility, the cost of transition, the ability of customer to
manage the transition, the level of risk during transition given other initiatives, the availability of other service providers,
changes in appetite for risk,
changes in the outsourcing
industry,
changes in the
legal and regulatory environment.
Strengths include customer development / maintenance, therapeutic / clinical product and disease - state knowledge,
managing a complex selling environment
in addition to an excellent work ethic and complying with the ever -
changing legal guidelines within the pharmaceutical
industry